Transaction #15969 · Form 4 · 0000875320-25-000242
VERTEX PHARMACEUTICALS INC / MA · Exercise / conversion · Common Stock
VERTEX PHARMACEUTICALS INC / MA · Transacted December 4, 2025 · Filed December 5, 2025
What does this filing report?
An SEC Form 4 filing for VERTEX PHARMACEUTICALS INC / MA records an exercise / conversion involving Common Stock on December 4, 2025. The reported quantity was 1. The filing date is December 5, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0000875320
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 1
- Reported price
- 91.05
- Reference value
- 91.05
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 24,027
- Ownership description
- Not reported
- SEC acceptance time
- Dec 5, 2025, 4:10 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- LEIDEN JEFFREY M ↗
Executive Chairman · Director
CIK 0001242825
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.
- F2
- Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3
- Open market sales reported on this line occurred at a weighted average price of $440.40 (range $440.04 to $441.00).
- F4
- Open market sales reported on this line occurred at a weighted average price of $441.26 (range $441.14 to $442.00).
- F5
- Open market sales reported on this line occurred at a weighted average price of $443.21 (range $442.94 to $443.93).
- F6
- Open market sales reported on this line occurred at a weighted average price of $444.36 (range $444.00 to $444.94).
- F7
- Open market sales reported on this line occurred at a weighted average price of $445.56 (range $445.00 to $445.82).
- F8
- Open market sales reported on this line occurred at a weighted average price of $447.05 (range $447.00 to $447.23).
- F9
- Open market sales reported on this line occurred at a weighted average price of $448.78 (range $448.18 to $449.12).
- F10
- Open market sales reported on this line occurred at a weighted average price of $449.84 (range $449.22 to $450.18).
- F11
- Open market sales reported on this line occurred at a weighted average price of $451.20 (range $450.71 to $451.70).
- F12
- Open market sales reported on this line occurred at a weighted average price of $452.20 (range $451.73 to $452.69).
- F13
- Open market sales reported on this line occurred at a weighted average price of $453.34 (range $452.91 to $453.70).
- F14
- Open market sales reported on this line occurred at a weighted average price of $455.22 (range $454.88 to $455.66).
- F15
- Fully vested.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.